Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 349
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GF66C19399DEN
Leaflet:

Download PDF Leaflet

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 16, 14, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumor (GIST) - Overview
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
AB Science SA
Advanced Accelerator Applications SA
Ariad Pharmaceuticals Inc
Arog Pharmaceuticals Inc
ArQule Inc
Array BioPharma Inc
Ascentage Pharma Group Corp Ltd
Astex Pharmaceuticals Inc
Blueprint Medicines Corp
Boston Biomedical Inc
Calithera Biosciences Inc
Celldex Therapeutics Inc
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
Merck & Co Inc
Natco Pharma Ltd
Nerviano Medical Sciences Srl
Novartis AG
Omeros Corp
Pharma Mar SA
Plexxikon Inc
Rhizen Pharmaceuticals SA
Taiho Pharmaceutical Co Ltd
Xencor Inc
Gastrointestinal Stromal Tumor (GIST) - Drug Profiles
aldoxorubicin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amcasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APG-1351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHMFLKIT-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenigacestat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCC-2618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-95573 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilixadencel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRCAN-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onalespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
R&D Progress
Peptide to Antagonize GRPR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexidartinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-9486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PM-184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-1126 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
umbralisib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vemurafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WBZ-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XmAb-18087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
Featured News & Press Releases
Nov 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFR alpha Genotypes
Nov 10, 2017: Deciphera Pharmaceuticals Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
Nov 01, 2017: Blueprint Medicines Announces Publication of BLU-285 Translational Data
Sep 11, 2017: Deciphera Pharmaceuticals Reports Updated Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the European Society of Medical Oncology 2017 Congress
Aug 31, 2017: Deciphera Pharmaceuticals to Present Updated Data from Ongoing Phase 1 Study of DCC-2618 at the 2017 European Society for Medical Clinical Oncology Annual Congress
Aug 02, 2017: Blueprint Medicines Provides Update on Clinical Program of its Cancer Drug, BLU-285
Jun 05, 2017: Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation
Jun 05, 2017: Deciphera Pharmaceuticals Reports Updated Phase 1 Clinical Study Results with DCC-2618 at 2017 American Society of Clinical Oncology Annual Meeting
May 18, 2017: Deciphera Pharmaceuticals to Report Phase 1 Clinical Study Results with DCC-2618 at the 2017 American Society of Clinical Oncology Annual Meeting
May 17, 2017: Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting
Apr 03, 2017: Translational Research Results Confirm The Broad Activity of DCC-2618 in GIST Patients With Difficult to Treat Drug Resistant KIT Mutations
Nov 30, 2016: Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
Nov 30, 2016: Results from 3 ground-breaking studies show early benefit to patients
Nov 16, 2016: Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene
Nov 15, 2016: Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications SA, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corp, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Celldex Therapeutics Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Co, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Exelixis Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Loxo Oncology Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Merck & Co Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences Srl, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corp, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Pharma Mar SA, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals SA, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Xencor Inc, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2017
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AB Science SA
Advanced Accelerator Applications SA
Ariad Pharmaceuticals Inc
Arog Pharmaceuticals Inc
ArQule Inc
Array BioPharma Inc
Ascentage Pharma Group Corp Ltd
Astex Pharmaceuticals Inc
Blueprint Medicines Corp
Boston Biomedical Inc
Calithera Biosciences Inc
Celldex Therapeutics Inc
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
Merck & Co Inc
Natco Pharma Ltd
Nerviano Medical Sciences Srl
Novartis AG
Omeros Corp
Pharma Mar SA
Plexxikon Inc
Rhizen Pharmaceuticals SA
Taiho Pharmaceutical Co Ltd
Xencor Inc
Skip to top


Ask Your Question

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: